-
公开(公告)号：US20240409653A1
公开(公告)日：2024-12-12
申请号：US18698354
申请日：2022-10-05
Applicant: GENMAB A/S , BIONTECH SE , MSD INTERNATIONAL BUSINESS GMBH
Inventor： Alexander MUIK , Kristina NÜRMBERGER , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN
Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
-
公开(公告)号：US20240335511A1
公开(公告)日：2024-10-10
申请号：US18268124
申请日：2021-12-20
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Lena Mareen KRANZ , Mathias VORMEHR , Sina FELLERMEIER-KOPF , Jan DIEKMANN , David EISEL
CPC classification number: A61K38/2046 , A61K9/5146 , A61K38/2013 , A61K38/38 , A61K48/0041 , A61P35/00 , C07K14/5418 , C07K14/55 , C07K14/765 , C07K2319/31
Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
-
公开(公告)号：US20210163616A1
公开(公告)日：2021-06-03
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20240262924A1
公开(公告)日：2024-08-08
申请号：US18570257
申请日：2022-06-20
Applicant: GENMAB A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria N. JURE-KUNKEL , Gaurav BAJAJ , Craig THALHAUSER , Nora PENCHEVA
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2827 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.
-
公开(公告)号：US20230295335A1
公开(公告)日：2023-09-21
申请号：US18184120
申请日：2023-03-15
Applicant: Genmab A/S , BioNTech SE
Inventor： Andreea IOAN , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , David P.E. SATIJN , Ugur SAHIN , Alexander MUIK , Kristina SCHÖDEL , Sina FELLERMEIER-KOPF , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/30 , C07K16/2878 , C07K2317/31 , C07K2317/92
Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
-
Patent Agency Ranking
公开(公告)号：US20220143144A1
公开(公告)日：2022-05-12
申请号：US17442568
申请日：2020-04-02
Applicant: BIONTECH SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Inventor： Ugur SAHIN , Mathias VORMEHR , Lena KRANZ , Sina FELLERMEIER-KOPF , Alexander MUIK , Daniel REIDENBACH , Mustafa DIKEN , Sebastian KREITER
Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.
-
公开(公告)号：US20240327544A1
公开(公告)日：2024-10-03
申请号：US18579086
申请日：2022-07-13
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur SAHIN , Alexander MUIK , Sina FELLERMEIER-KOPF , Yali FU , Homer ADAMS, III , Gaurav BAJAJ , Brandon HIGGS , Mark FERESHTEH , Vanessa SPIRES , Jordan BLUM , Patricia GARRIDO CASTRO , Michelle NIEWOOD , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , Jost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/468 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76
Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
8.发明公开公开(公告)号：US20230365693A1
公开(公告)日：2023-11-16
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur SAHIN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Alexander MUIK , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Patricia GARRIDO CASTRO , Jordan BLUM , Lars GUELEN , Joost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
公开(公告)号：US20200165349A1
公开(公告)日：2020-05-28
申请号：US16779011
申请日：2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20240109972A1
公开(公告)日：2024-04-04
申请号：US18038818
申请日：2021-12-07
Applicant: Genmab A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria JURE-KUNKEL , Manish GUPTA , Tahamtan AHMADI , Kathy AMIRI , Gaurav BAJAJ
IPC: C07K16/28 , A61K31/337 , A61K45/06 , A61P35/00
CPC classification number: C07K16/2878 , A61K31/337 , A61K45/06 , A61P35/00 , C07K16/2827 , A61K2039/505
Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.036 seconds)
